INTRODUCTION {#s1}
============

Pancreatic cancer (PC) is the fourth leading cause of cancer-related death in the United States \[[@R1]\]. Owing to late stage at the time of diagnosis, there are just 10%-20% of patients eligible for surgical treatment \[[@R2]\]. Although the surgical procedure of pancreatic cancer over the last decades has improved strongly, it needs some more effective treatments and adjuvant therapies against PC.

The relationship between PC and diabetes mellitus (DM) has been increasingly recognized over the past decades. Studies suggest that DM plays a pivotal role in cancer risk and progression \[[@R3]--[@R5]\]. Although we have not fully understood the mechanisms of increased risk of cancer incidence with DM, hyperinsulinemia may influence the neoplastic process through its effects on enhancing cancer cell proliferation, survival, and invasion and inhibiting apoptosis in the insulin-like growth factor-I (IGF-I) signaling pathway \[[@R6], [@R7]\]. There are an increasing number of experimental evidence and epidemiologic studies to show that ADMs may modify the prognosis of PC. Some studies suggest that metformin may improve outcome of patients with diabetes and pancreatic cancer \[[@R8]--[@R13]\], whereas others have not revealed beneficial effect \[[@R14]--[@R18]\]. Besides, some studies suggest that insulin may highlight risk of PC mortality \[[@R19], [@R20]\], whereas others have not affected the survival \[[@R8], [@R11]\]. Due to controversial results among studies, we thus carry out this meta-analysis to investigate the prognostic value of ADMs use (as compared with non-user) among PC patients.

RESULTS {#s2}
=======

Description of the included studies {#s2_1}
-----------------------------------

The initial database search yielded a total of 3326 references for eligibility. After excluding the duplicates and screening the remaining title and abstract, 42 potentially relevant studies were identified for further review. After selection, a total of 14 publications met our inclusion criteria (Figure [1](#F1){ref-type="fig"}). The clinical features of included studies were summarized in Table [1](#T1){ref-type="table"}. In summary, 13 studies investigated the survival outcomes for patients of metformin use, 5 for insulin use, 2 for SUs use and 2 for TZDs use. The median follow-up time ranged from 0.77 to 12 years. 5 studies were carried out in USA, 3 in Europe and 2 in Asia. Several cohorts were adjusted for some conventional influential factors, including age, sex, disease stage. Six studies involved PC patients with I-IV disease stages, and two with stage IV. Assessment of methodological quality for cohort studies yielded a score range of 7 to 9, and 7 of 12 studies had a score of 8 or above ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

![Flow diagram of the selection process of studies investigating effect of anti-diabetic medications use on pancreatic cancer survival](oncotarget-08-62349-g001){#F1}

###### Baseline characteristics of the included studies on survival outcomes of anti-diabetic medications use for pancreatic cancer patients

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors               Study design     Country/Setting         No. of hospitals involved   Study period   Exposure ascertainment           Median follow-up\   ADMs user/non-user   Sample size   Types of ADMs                 Disease stage   Survival end points   Adjusted variables
                                                                                                                                             (months)                                                                                                                   
  --------------------- ---------------- ----------------------- --------------------------- -------------- -------------------------------- ------------------- -------------------- ------------- ----------------------------- --------------- --------------------- -------------------------------------------------------------------------
  Reni et al.           RCT              Italy; hospital based   Single                      2010-2014      RCT                              NR                  31/29                60            Metformin                     IV              OS, PFS               NR

  Lee et al.            Retrospective\   Korea;\                 Single                      2005-2013      Medical records, self-reported   10.3                117/120              237           Metformin\                    I-IV            OS                    CA199 levels, tumor size and stage, performance status, DDP4 inhibitors
                        cohort           hospital\                                                                                                                                                  TZDs\                                                               
                                         based                                                                                                                                                      SU\                                                                 
                                                                                                                                                                                                    insulin                                                             

  Kozak et al.          Retrospective\   USA;\                   Single                      1998-2013      Electronic\                      11.23               18/153               171           Metformin                     I-IV            OS, DFS               Age, sex, smoking status, surgery, tumor stage, treatment regimen
                        cohort           hospital\                                                          medical records                                                                                                                                             
                                         based                                                                                                                                                                                                                          

  Choi et al.           Retrospective\   Korea;\                 Single                      2003-2010      Electronic\                      10.2                56/127               183           Metformin\                    I-IV            OS                    Performance status, diabetes, cancer extent, weight loss during therapy
                        cohort           hospital\                                                          medical records                                                                         SU\                                                                 
                                         based                                                                                                                                                      insulin                                                             

  Chaiteerakij et al.   Retrospective\   USA;\                   Single                      2000-2011      Electronic\                      9.26                366/614              980           Metformin                     I-IV            OS                    Age, sex, BMI,\
                        cohort           hospital\                                                          medical records                                                                                                                                             stage
                                         based                                                                                                                                                                                                                          

  Cerullo et al.        Retrospective\   USA;\                   Multiple                    2010-2012      Electronic\                      16.5                456/2937             3393          Metformin                     I-IV            OS                    Age, sex, region, Charlson index, treatment regimen
                        cohort           population\                                                        medical records                                                                                                                                             
                                         based                                                                                                                                                                                                                          

  Ambe et al.           Prospective\     USA;\                   Single                      1986-2013      Electronic\                      19                  19/25                44            Metformin                     I-II            OS                    Age, BMI, surgery, diabetes, CA199 levels, stage, regional nodes
                        cohort           hospital\                                                          medical records                                                                                                                                             
                                         based                                                                                                                                                                                                                          

  Kordes et al.         RCT              Netherlands;\           Multiple                    2010-2014      RCT                              28.1                61/60                121           Metformin                     IV              OS, PFS               Age, sex, performance status, stage, tumor location, surgery, diabetes
                                         hospital\                                                                                                                                                                                                                      
                                         based                                                                                                                                                                                                                          

  Tseng et al.          Retrospective\   China;\                 Multiple                    1995-2006      Structured\                      12 years            5927/80970           86897         Insulin                       I-IV            OS                    Age, sex, diabetes,\
                        cohort           population\                                                        questionnaire interview                                                                                                                                     BMI, smoking, region
                                         based                                                                                                                                                                                                                          

  Hwang et al.          Retrospective\   United Kingdom;\        Multiple                    2003-2010      Electronic\                      NR                  247/269              516           Metformin                     I-IV            OS                    Age, sex, diabetes duration and complications,\
                        cohort           population\                                                        medical records                                                                                                                                             Charlson index, BMI, GFR, smoking, other ADMs and HbA1c.
                                         based                                                                                                                                                                                                                          

  Sadeghi et al.        Retrospective\   USA;\                   Single                      2000-2009      Interviews,\                     11.4                117/185              302           Metformin                     I-IV            OS                    Disease stage, CA199 level, tumor size and site, performance status
                        cohort           hospital\                                                          medical records.                                                                                                                                            
                                         based                                                                                                                                                                                                                          

  Amin et al.           Retrospective\   USA;\                   Multiple                    2007-2011      NR                               NR                  589/258              847           Metformin                     I-IV            OS                    Demographic factors, stage, income, diabetic complications,\
                        cohort           population\                                                                                                                                                                                                                    Charlson index, other ADMs
                                         based                                                                                                                                                                                                                          

  Jang et al.           Prospective\     Korea;\                 Multiple                    2005-2011      Prescription\                    NR                  530/234              764           Metformin                     I-IV            OS                    NR
                        cohort           population\                                                        information                                                                                                                                                 
                                         based                                                                                                                                                                                                                          

  Jeon et al.           Retrospective\   USA;\                   Multiple                    2008-2009      NR                               NR                  132/131              263           Insulin/SUs; metformin/TZDs   I-IV            OS                    Age, sex, race,\
                        cohort           population\                                                                                                                                                                                                                    stage and chemotherapy
                                         based                                                                                                                                                                                                                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADMs, anti-diabetic medications; BMI, body mass index; DFS, disease-free survival; NR, not reported; OS, overall survival; PFS, progression-free survival; RCT, randomized controlled trial; SUs, sulfonylureas; TZDs, thiazolidinediones.

Metformin use and PC survival {#s2_2}
-----------------------------

The combined HR for the OS comparing metformin use versus non-use was 0.77 (95% CI=0.68-0.87) with moderate inter-study heterogeneity (I^2^=52.9%, p=0.02) (Figure [2A](#F2){ref-type="fig"}) for cohort studies. Figure [2B](#F2){ref-type="fig"} presents the HR (HR=1.22; 95% CI=0.76-1.95) for PFS. No significant survival benefit was noted for randomized controlled trials (RCTs) (HR=1.20, 95% CI=0.84-1.72).

![Meta-analysis of the associations between metformin use and pancreatic cancer overall survival (A), and progression-free surival (B)\
CI, confidence interval; HR, hazard ratio; W (random): Weights (random effects model).](oncotarget-08-62349-g002){#F2}

We summarized the subgroup analyses for OS in Table [2](#T2){ref-type="table"} to further test potential sources of heterogeneity among certain major clinical characteristics of the included studies. The pooled HRs for the majority of the subgroups did not change significantly stratified by some major study characteristics, including the study design and setting, study country, the number of hospitals, sample size, adjusted variables or the scores of Newcastle--Ottawa Quality Assessment Scale. A possible interaction was found in the subgroup of sample size. Results of analyses limited to studies with some of the main variable adjusted (age, sex and tumor stage) are also presented in Table [2](#T2){ref-type="table"}. For studies with these three variables adjusted, a null prognostic association of metformin use was noted. Nevertheless, further studies should be conducted to examine the true survival benefit of metformin in PC patients due to the small number of studies involved in these subgroups.

###### Subgroup analyses of the associations between metformin use and overall survival for cohort studies

  Comparison variables       Overall survival                              
  -------------------------- ------------------ ------ ------------------- --------
   Total                     11                 52.9   0.77(0.68 - 0.87)   NA
  Study design                                                             0.534
   Prospective cohort        2                  0      0.72(0.61 - 0.86)   
   Retrospective cohort      9                  58.9   0.78(0.67 -0.90)    
  Study setting                                                            0.111
   Hospital based            6                  64.5   0.67(0.53 - 0.85)   
   Population based          5                  33.6   0.84(0.73 - 0.96)   
  Study region                                                             0.214
   USA                       7                  47.2   0.78(0.67 - 0.92)   
   Europe                    1                         1.09(0.80 - 1.48)   
   Asia                      3                  0      0.69(0.60 - 0.79)   
  Hospital number                                                          0.111
   Single                    6                  64.5   0.67(0.53 - 0.85)   
   Multiple                  5                  33.6   0.84(0.73 -0.96)    
  Sample size                                                              0.0024
   ≥500                      5                  44.1   0.86(0.76 -0.97)    
   \<500                     6                  0      0.63(0.54 - 0.74)   
  Main variable adjusted\*                                                 0.276
   Yes                       5                  57.8   0.83(0.68 -1.03)    
   No                        6                  30.8   0.73(0.64 -0.83)    
  NOS scale                                                                0.359
   ≥8                        6                  59.4   0.73(0.59 - 0.90)   
   \<8                       5                  36.2   0.82(0.71 - 0.94)   

CI, confidence interval; HR, hazard ratio; Main variable adjusted\*, Age, sex, stage; NA; not available.

Sensitivity analysis by omitting one single study each time and pooling the others indicated that the pooled HRs was not significantly altered. Funnel plot for publication bias did not show asymmetry (Figure [3](#F3){ref-type="fig"}). Further Egger's test (*P*=0.135) or Begg's test (*P*=0.436) also did not found a certain degree publication bias.

![Funnel plot of studies investigating association between metformin use and pancreatic cancer survival for cohort studies](oncotarget-08-62349-g003){#F3}

Other ADMs use and PC survival {#s2_3}
------------------------------

Five studies investigated the impact of insulin use and PC survival and there was no significant association between insulin use and PC survival (HR=1.18, 95% CI=0.83-1.69; Figure [4A](#F4){ref-type="fig"}). We also did not find significant association between SUs (HR=1.03, 95% CI=0.81-1.30; Figure [4B](#F4){ref-type="fig"}) or TZDs (HR=0.84, 95% CI=0.58-1.22; Figure [4C](#F4){ref-type="fig"}) use and PC survival.
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DISCUSSION {#s3}
==========

This meta-analysis investigated the association between ADMs (metformin, insulin, SUs and TZDs) treatment and survival of PC. We found metformin treatment was significantly associated with favorable OS of PC patients (HR=0.77, 95% CI=0.68-0.87) in cohort studies, but was not significantly associated with PFS (HR=1.22; 95% CI=0.76-1.95) for RCTs. We also found no survival benefits of other ADMs, such as insulin, SUs or TZDs, for PC patients.

Several potential mechanisms may explain the associations for the fact that conventional ADMs may alter the risk of multiple malignancies. It was reported that metformin has been shown to play an important anticancer role in multiple ways including insulin-dependent or independent manners \[[@R21]\]. A recent study found that SUs can induce cell proliferation and had an effect of carcinogenesis by promoting insulin secretion \[[@R22]\]. Moreover, previous *in vitro* studies showed that TZDs had an impact on cell growth arrest and apoptosis and the inhibition of cancer cell invasion \[[@R23]\].

Several important strengths of this meta-analysis should be addressed. Firstly, to the best of our knowledge, this is the first systematic review regarding the associations between the use of ADMs and prognosis of PC. Secondly, comprehensive and reproducible search strategies were developed to identify all relevant studies or trials in the major databases without language limitations. Thirdly, we investigated the most commonly used ADMs including metformin, SUs, TZDs and insulin and conducted a meta-analysis for both RCTs and cohort studies. Fourthly, more than 90000 participants were included to quantitatively assess the association between ADMs use and PC prognosis, which was the most comprehensive synthesis of the evidence on this topic ever today. Finally, several subgroup analyses were carried out for some of the important variables, such as study design and setting, research region, number of research hospital, main variable adjusted and quality score. The results showed consistency across subgroups.

Still there are limitations in our systematic review. Firstly, the number of studies for each medication involved in this meta-analysis was relatively small except for metformin, and thus it is difficult to draw definite conclusions for the limited statistical power in SUs, TZDs or insulin subset. Secondly, almost none of the included studies had dose or duration-response analysis for certain ADMs, so it is impossible for us to perform this kind of analysis. Therefore, further study should be focused on this aspect. Thirdly, although some major confounders including age, sex and disease stage were identified and adjusted for some of the included studies, some other variables (such as tumor size, body mass index or chemotherapy) could influence our exploration of associations between ADMs and PC survival. Last but not the least, although we did not find significant publication bias for metformin subset in cohort studies, we could not totally exclude potential impact of unpublished studies on the pooled results, which might have resulted in reporting bias. However, the adjusted estimates of the results using the trim and fill methods remained unchanged, indicating the stability of our analysis.

In summary, the results from this meta-analysis revealed that in cohort studies, metformin, not other ADMs was associated with improved OS in PC patients. However, due to limited number of studies investigating other ADMs, further large-scale studies are warranted to determine these associations.

MATERIALS AND METHODS {#s4}
=====================

Literature search and study selection {#s4_1}
-------------------------------------

Based on the PRISMA statement \[[@R24]\], we performed a comprehensive literature search in Pubmed and Embase databases up to August 2016 for relevant citations without language restrictions. We used the search strategies ([Supplementary Table 2](#SD1){ref-type="supplementary-material"} and [Table 3](#SD1){ref-type="supplementary-material"}) that included Medical Subject Headings and Emtree headings combined key words relating to the prognostic effect of ADMs among PC patients. We also manually scanned the reference lists from the extracted relevant research papers, previous reviews and meta-analysis for additional possible publications.

We included published studies providing aggregate data if they met the following criteria: (1) evaluated any prognostic information in PC patients comparing ADMs users with non-users, (2) reported a summary statistic of hazard ratios (HRs) with 95% confidence intervals (CIs) or provided date for calculation as described by Parmar et al \[[@R25]\]. RCTs or observational studies were eligible for this meta-analysis. If there were more than one studies from the same cohort, we selected the most detailed or recent one for analysis. All the studies reporting prognostic information, including overall survival (OS), and progression-free survival (PFS), were selected in the main analyses ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). Two independent investigators (Zhou and Gong) conducted the study selection from eligible studies.

Data extraction {#s4_2}
---------------

Two independent investigators (Zhou and Gong) selected articles and extracted data from eligible studies, evaluated the quality of each study and any discrepancies were resolved by a consensus discussion with a third investigator (Tan). The characteristics recorded were the first author's last name, publication year, country of the population studied, study design, study setting, number of hospitals involved, time period of study, information source for exposure ascertainment and outcome assessment, total number of persons in each group (exposed vs. not exposed), sample size, types of ADMs, stage, mean F/U (months), survival endpoints and adjustment variables HR, and 95% confidence intervals (CIs) with adjustment for confounding factors. The methodological quality of each study was evaluated using the Newcastle-Ottawa quality assessment scale \[[@R26]\], in which three domains including cohort selection, comparability, and outcome were evaluated with a score range of 0 to 9 with nine representing the highest quality.

Statistical analysis {#s4_3}
--------------------

We used STATA statistical software (version 12.0, StataCorp LP, College Station, TX) and R statistical software (version 3.3.1) to perform the meta-analysis. Survival estimates with full adjustments for known confounders of included studies were abstracted. Summary data reporting HRs with corresponding 95% CIs estimated from Cox proportional hazards models were pooled with random-effects model \[[@R27]\]. The data regarding the association of ADMs (use vs. no use) with survival outcomes were pooled separately. We used the Cochrane Q statistic (with a P value less than 0.10 considering statistically significant) and the *I*^*2*^ statistic (with an *I*^*2*^ exceeding 50% indicating significant heterogeneity) to test for between-study heterogeneity \[[@R28]\]. Metformin usage and OS for PC patients were explored for primary meta-analysis. Other outcome measures such as PFS and Disease-free survival (DFS) were also evaluated. Owing to the limited studies for PFS and DFS, we combined the data of PFS and DFS as one outcome for the meta-analysis. We performed sensitivity analyses to explore the reasons for statistical heterogeneity. The risk of publication bias was assessed visually by inspecting of a funnel plot and statistically by using Egger\'s or Begg\'s regression model \[[@R29]\]. We further ascertained the number of missing studies using Duval and Tweedie's trim and fill method to adjust the summary hazard ratio based on all the studies including the hypothesized missing ones \[[@R30]\]. All statistical analyses were two-sided and a P-value less than 0.05 was considered significant.
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